MYD88 — patent landscape

Top predicted compounds (top 20 by supporting neighbours, then confidence)

Compound	Confidence	Supporting neighbours
SCHEMBL29078406	0.68	2/20
SCHEMBL30205259	0.59	2/20
SCHEMBL28455743	1.00	1/20
SCHEMBL28954767	1.00	1/20
SCHEMBL28450337	0.89	1/20
SCHEMBL30205153	0.86	1/20
SCHEMBL28954891	0.85	1/20
SCHEMBL30205183	0.80	1/20
SCHEMBL28954867	0.73	1/20
SCHEMBL30205143	0.73	1/20
SCHEMBL28954835	0.73	1/20
SCHEMBL28954865	0.73	1/20
SCHEMBL30205169	0.73	1/20
SCHEMBL30205170	0.73	1/20
SCHEMBL28954776	0.71	1/20
SCHEMBL28954834	0.64	1/20
SCHEMBL27235580	0.63	1/20
SCHEMBL30173490	0.63	1/20
SCHEMBL28954884	0.62	1/20
SCHEMBL30205256	0.62	1/20

Clinical trials — most relevant to MYD88 by text similarity (a relevance ranking, not an exhaustive list)

Trial	Phase	Status
Centocor Microarray Study of Patients	PHASE4	COMPLETED
Bacillus Calmette-guérin Vaccination to Prevent Infections of the Elderly	PHASE4	COMPLETED
Effects of BCG on Immune Response	PHASE2/PHASE3	COMPLETED
Efficacy of Vitamin D on the Clinical Management of Pediatric Patients With Asthma	PHASE3	UNKNOWN
TGR-1202 and Ibrutinib in Treating Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma	PHASE2	COMPLETED
Toll-like Receptor (TLR) Ligand Matured Dendritic Cell Vaccination in Melanoma Patients	PHASE1/PHASE2	COMPLETED
Ibrutinib + Venetoclax in Untreated WM	PHASE2	ACTIVE_NOT_RECRUITING
Single-step Antigen Loading and TLR Activation of Dendritic Cells in Melanoma Patients	PHASE1/PHASE2	COMPLETED
NeoCARD: Anthracycline-Free Neoadjuvant Chemoimmunotherapy in Triple-Negative Breast Cancer Patients	PHASE2	RECRUITING
Tocilizumab in the Treatment of Refractory Polymyositis and Dermatomyositis	PHASE2	COMPLETED
Platin-based Chemotherapeutics to Enhance Dendritic Cell Vaccine Efficacy in Melanoma Patients	PHASE2	COMPLETED
Nonmyeloablative Allogeneic Stem Cell Transplantation From HLA-Matched Unrelated Donor for the Treatment of Hematologic Disorders	PHASE2	COMPLETED
The Effects of GLA on Human Volunteers	PHASE1	COMPLETED
Combination of Tagraxofusp With Pacritinib in Patients With Intermediate-1 or Higher Myelofibrosis, Who Have Had Prior Therapy With the Approved JAK Inhibitors or in Which Therapy With the Approved JAK Inhibitors is Not Appropriate, Contraindicated or Declined	EARLY_PHASE1	RECRUITING
Detection of Recurrent Mutations in Waldenström's Disease	nan	COMPLETED
Heterogeneity of Dendritic Cells in Colon and Non-small Cell Lung Cancer	nan	UNKNOWN
Natural History of HPV From Infection to Neoplasia in Adolescents and Young Women	nan	COMPLETED
Toll-like Receptor 2 Gene Polymorphism, Serum Cytokines and Susceptibility to Disease Severity or Treatment Response of Pulmonary Tuberculosis	nan	COMPLETED
Safety and Efficacy of a Non-replicating ChAdOx1 Vector Vaccine AZD1222 (COVISHIELD), for Prevention of COVID-19 in Patients With Liver Cirrhosis	nan	UNKNOWN
MERTK Signalling in Monocytes/Macrophages in Patients With Liver Disease	nan	COMPLETED
The Role of Neutrophil CD64 and Soluble Triggering Receptor Expressed on Myeloid Cells 1 in Neonatal Sepsis	nan	UNKNOWN
Deep Phenotyping of Cutaneous Lupus Erythematosus	nan	UNKNOWN
Prognostic Analyses on a Validation Series of Patients With Waldenström's Disease	nan	RECRUITING
Studying Biomarkers in Cell Samples From Young Patients With Acute Myeloid Leukemia	nan	COMPLETED
Prognostic Biomarkers in Samples From Young Patients With Acute Myeloid Leukemia	nan	COMPLETED
OveRcoming immunosupprEssion aNd rebAlancing the Immune reSponSe in ovAriaN CancEr Study	nan	RECRUITING
Microbiota in COVID-19 Patients for Future Therapeutic and Preventive Approaches	nan	UNKNOWN
Neuro-Immune Interactions in the Gut	nan	COMPLETED
Comprehensive Molecular and Clinical Evaluation of Pediatric and Adult MDS	nan	RECRUITING
Innate Immune Functions of Immature Neutrophils	nan	UNKNOWN

Related proteins — ESM-2 sequence neighbours (a MYD88 binder may also engage these)

Protein	Name	Similarity
B3Y680	—	1.000	B3Y680 →
B3Y681	—	1.000	B3Y681 →
B3Y683	—	1.000	B3Y683 →
B3Y679	—	1.000	B3Y679 →
B3Y678	—	1.000	B3Y678 →
B3Y682	—	1.000	B3Y682 →
B6CJX2	—	1.000	B6CJX2 →
A2TF48	—	1.000	A2TF48 →
Q599T9	—	1.000	Q599T9 →
C8BKC7	—	0.999	C8BKC7 →
A5HNF6	—	0.997	A5HNF6 →
P22366	—	0.992	P22366 →
Q6Y1S1	—	0.991	Q6Y1S1 →
A8QMS7	—	0.987	A8QMS7 →
B3SRQ2	—	0.985	B3SRQ2 →
Q5XJ85	—	0.985	Q5XJ85 →
Q28DJ2	—	0.982	Q28DJ2 →
Q4LBC6	—	0.981	Q4LBC6 →
Q5FWM2	—	0.977	Q5FWM2 →
Q9DF60	—	0.973	Q9DF60 →
Q13158	—	0.965	Q13158 →
Q28DV7	—	0.963	Q28DV7 →
Q7ZYP6	—	0.961	Q7ZYP6 →
P47823	—	0.961	P47823 →
Q61160	—	0.961	Q61160 →
EIF2B5	Translation initiation factor eIF2B subunit epsilon	0.960	landscape →
O02697	—	0.960	O02697 →
Q645M6	—	0.959	Q645M6 →
Q9JIM4	—	0.959	Q9JIM4 →
P52735	—	0.959	P52735 →